235 Results

People

  1. Brentjens
    Brentjens
  2. Perales
    Perales
  3. Sadelain
    Sadelain
  4. Adusumilli
    Adusumilli
  5. Giralt
    Giralt
  6. Park
    Park
  7. Riviere
    Riviere
  8. Shouval
    Shouval
  9. Shah
    Shah
  10. Curran
    Curran

Groups

  1. Department of Medicine (171)
  2. Hematologic Malignancies, Division of (159)
  3. Center for Hematologic Malignancies (141)
  4. GSK Faculty (92)
  5. Hematologic Malignancies Research (76)
  6. Adult Leukemia (60)
  7. Sloan Kettering Institute Postdocs (56)
  8. Sloan Kettering Institute Faculty (52)
  9. Bone Marrow Transplant (49)
  10. Molecular Pharmacology and Chemistry Program Faculty (42)
  1. "chimeric antigen receptor"
Formats
  1. Journal Article (158)
  2. Review (50)
  3. Editorial (12)
  4. Guidelines (4)
  5. Correspondence (3)
  6. Book Section (2)
  7. Meeting Abstract (2)
  8. Miscellaneous (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (171)
  2. Hematologic Malignancies, Division of (159)
  3. Center for Hematologic Malignancies (141)
  4. GSK Faculty (92)
  5. Hematologic Malignancies Research (76)
  6. Adult Leukemia (60)

More Groups

People
  1. Renier Brentjens (40)
  2. Michel Sadelain (37)
  3. Miguel-Angel Perales (25)
  4. Jae Park (17)
  5. Isabelle Riviere (16)
  6. Prasad Adusumilli (14)

More People

Years
  1. 2025 (24)
  2. 2024 (54)
  3. 2023 (27)
  4. 2022 (11)
  5. 2021 (4)
  6. 2020 (15)

More Years

Publications
  1. Blood (11)
  2. Haematologica (9)
  3. Transplantation and Cellular Therapy (9)
  4. Molecular Therapy (8)
  5. Frontiers in Oncology (7)
  6. Blood Advances (6)

More Publications

Publishers
  1. Nature Publishing Group (33)
  2. Elsevier Inc. (32)
  3. American Society of Hematology (20)
  4. Cell Press (11)
  5. Biomed Central Ltd (10)
  6. Frontiers Media S.A. (10)

More Publishers

Results (235)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Suppressive effects of obesity on NK cells: Is it time to incorporate obesity as a clinical variable for NK cell-based cancer immunotherapy regimens?
    Editorial

    Canter, R. J.; Judge, S. J.; Collins, C. P.; Yoon, D. J.; Murphy, W. J.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
    Editorial

    Levine, B. L.; Pasquini, M. C.; Connolly, J. E.; Porter, D. L.; Gustafson, M. P.; Boelens, J. J.; Horwitz, E. M.; Grupp, S. A.; Maus, M. V.; Locke, F. L.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Structural basis for antibody recognition of the proximal MUC16 ectodomain
    Journal Article

    Lee, K.; Perry, K.; Xu, M.; Veillard, I.; Kumar, R.; Rao, T. D.; Rueda, B. R.; Spriggs, D. R.; Yeku, O. O.
    Journal of Ovarian Research (2024)

    Fulltext@MSK | Save
  • Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy
    Journal Article

    Infante, M. S.; Nemirovsky, D.; Devlin, S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Chung, D. J.; Politikos, I.; Barker, J.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T cell therapy for myeloma: Where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy
    Guidelines

    Anderson, L. D. Jr; Dhakal, B.; Jain, T.; Oluwole, O. O.; Shah, G. L.; Sidana, S.; Perales, M. A.; Pasquini, M. C.
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    Journal Article

    Hess, G.; Dreyling, M.; Oberic, L.; Gine, E.; Zinzani, P. L.; Linton, K.; Vilmar, A.; Jerkeman, M.; Chen, J. M. H.; Ohler, A.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function
    Journal Article

    Jain, N.; Zhao, Z.; Koche, R. P.; Antelope, C.; Gozlan, Y.; Montalbano, A.; Brocks, D.; Lopez, M.; Dobrin, A.; Shi, Y.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma
    Journal Article

    Fried, S.; Shkury, E.; Itzhaki, O.; Sdayoor, I.; Yerushalmi, R.; Shem-Tov, N.; Danylesko, I.; Jacoby, E.; Shouval, R.; Kedmi, M.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement
    Journal Article

    Ryan, C. E.; Zon, R. L.; Redd, R.; Fisher, D. C.; Shouval, R.; Kumar, A.; Crombie, J. L.; Sadrzadeh, H.; Kim, A. I.; Nayak, L.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save